1-3 of 3
Jiuxiang Zhu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

Ping-Hui Tseng, Ho-Pi Lin, Jiuxiang Zhu, Kuen-Feng Chen, Erinn M. Hade, Donn C. Young, John C. Byrd, Michael Grever, Kara Johnson, Brian J. Druker, Ching-Shih Chen
Journal: Blood
Blood (2005) 105 (10): 4021–4027.
https://doi.org/10.1182/blood-2004-07-2967
Published: 2005
Journal Articles

A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2–independent mechanism

Amy J. Johnson, Lisa L. Smith, Jiuxiang Zhu, Nyla A. Heerema, Sara Jefferson, Andrew Mone, Michael Grever, Ching-Shih Chen, John C. Byrd
Journal: Blood
Blood (2005) 105 (6): 2504–2509.
https://doi.org/10.1182/blood-2004-05-1957
Published: 2005
Journal Articles

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Amy Johnson, PhD, Lisa Smith, Jiuxiang Zhu, Nyla Heerema, PhD, Sara Guster, Andrew Mone, MD, PhD, Michael Grever, MD, Ching-Shih Chen, PhD, John Byrd, MD
Journal: Blood
Blood (2004) 104 (11): 3471.
https://doi.org/10.1182/blood.V104.11.3471.3471
Published: 2004